Biome Australia Limited
Biome Australia Limited (BIO.AX) Stock Competitors & Peer Comparison
See (BIO.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO.AX | A$0.38 | -2.56% | 85.7M | -38.50 | -A$0.01 | N/A |
| CSL.AX | A$140.97 | -0.05% | 68.4B | 16.27 | A$8.67 | +3.03% |
| TLX.AX | A$10.94 | -2.58% | 3.8B | -376.33 | -A$0.03 | N/A |
| MSB.AX | A$2.06 | -3.97% | 2.7B | -21.10 | -A$0.10 | N/A |
| NEU.AX | A$11.61 | -2.85% | 1.5B | 51.13 | A$0.23 | N/A |
| CU6.AX | A$3.64 | -4.09% | 1.4B | -13.68 | -A$0.28 | N/A |
| PYC.AX | A$1.41 | -3.44% | 825M | -17.69 | -A$0.08 | N/A |
| OPT.AX | A$0.60 | +0.00% | 820.8M | -1.40 | -A$0.43 | N/A |
| CUV.AX | A$9.72 | -4.05% | 498.3M | 15.52 | A$0.64 | +0.50% |
| RAC.AX | A$2.11 | -7.46% | 394.3M | -43.40 | -A$0.05 | N/A |
Stock Comparison
BIO.AX vs CSL.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, CSL.AX has a market cap of 68.4B. Regarding current trading prices, BIO.AX is priced at A$0.38, while CSL.AX trades at A$140.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas CSL.AX's P/E ratio is 16.27. In terms of profitability, BIO.AX's ROE is +0.18%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, BIO.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CSL.AX's competition here
BIO.AX vs TLX.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, TLX.AX has a market cap of 3.8B. Regarding current trading prices, BIO.AX is priced at A$0.38, while TLX.AX trades at A$10.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas TLX.AX's P/E ratio is -376.33. In terms of profitability, BIO.AX's ROE is +0.18%, compared to TLX.AX's ROE of -0.02%. Regarding short-term risk, BIO.AX is more volatile compared to TLX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check TLX.AX's competition here
BIO.AX vs MSB.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, MSB.AX has a market cap of 2.7B. Regarding current trading prices, BIO.AX is priced at A$0.38, while MSB.AX trades at A$2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas MSB.AX's P/E ratio is -21.10. In terms of profitability, BIO.AX's ROE is +0.18%, compared to MSB.AX's ROE of -0.18%. Regarding short-term risk, BIO.AX is more volatile compared to MSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check MSB.AX's competition here
BIO.AX vs NEU.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, NEU.AX has a market cap of 1.5B. Regarding current trading prices, BIO.AX is priced at A$0.38, while NEU.AX trades at A$11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas NEU.AX's P/E ratio is 51.13. In terms of profitability, BIO.AX's ROE is +0.18%, compared to NEU.AX's ROE of +0.09%. Regarding short-term risk, BIO.AX is more volatile compared to NEU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check NEU.AX's competition here
BIO.AX vs CU6.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, CU6.AX has a market cap of 1.4B. Regarding current trading prices, BIO.AX is priced at A$0.38, while CU6.AX trades at A$3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas CU6.AX's P/E ratio is -13.68. In terms of profitability, BIO.AX's ROE is +0.18%, compared to CU6.AX's ROE of -0.60%. Regarding short-term risk, BIO.AX is less volatile compared to CU6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check CU6.AX's competition here
BIO.AX vs PYC.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, PYC.AX has a market cap of 825M. Regarding current trading prices, BIO.AX is priced at A$0.38, while PYC.AX trades at A$1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas PYC.AX's P/E ratio is -17.69. In terms of profitability, BIO.AX's ROE is +0.18%, compared to PYC.AX's ROE of -0.30%. Regarding short-term risk, BIO.AX is more volatile compared to PYC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PYC.AX's competition here
BIO.AX vs OPT.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, OPT.AX has a market cap of 820.8M. Regarding current trading prices, BIO.AX is priced at A$0.38, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas OPT.AX's P/E ratio is -1.40. In terms of profitability, BIO.AX's ROE is +0.18%, compared to OPT.AX's ROE of +1.32%. Regarding short-term risk, BIO.AX is more volatile compared to OPT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check OPT.AX's competition here
BIO.AX vs CUV.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, CUV.AX has a market cap of 498.3M. Regarding current trading prices, BIO.AX is priced at A$0.38, while CUV.AX trades at A$9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas CUV.AX's P/E ratio is 15.52. In terms of profitability, BIO.AX's ROE is +0.18%, compared to CUV.AX's ROE of +0.13%. Regarding short-term risk, BIO.AX is more volatile compared to CUV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CUV.AX's competition here
BIO.AX vs RAC.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, RAC.AX has a market cap of 394.3M. Regarding current trading prices, BIO.AX is priced at A$0.38, while RAC.AX trades at A$2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas RAC.AX's P/E ratio is -43.40. In terms of profitability, BIO.AX's ROE is +0.18%, compared to RAC.AX's ROE of -0.47%. Regarding short-term risk, BIO.AX is less volatile compared to RAC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check RAC.AX's competition here
BIO.AX vs DXB.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, DXB.AX has a market cap of 210.1M. Regarding current trading prices, BIO.AX is priced at A$0.38, while DXB.AX trades at A$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas DXB.AX's P/E ratio is -11.67. In terms of profitability, BIO.AX's ROE is +0.18%, compared to DXB.AX's ROE of -2.79%. Regarding short-term risk, BIO.AX is less volatile compared to DXB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check DXB.AX's competition here
BIO.AX vs OCC.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, OCC.AX has a market cap of 179.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while OCC.AX trades at A$0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas OCC.AX's P/E ratio is -16.20. In terms of profitability, BIO.AX's ROE is +0.18%, compared to OCC.AX's ROE of -0.45%. Regarding short-term risk, BIO.AX is less volatile compared to OCC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check OCC.AX's competition here
BIO.AX vs SPL.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, SPL.AX has a market cap of 172.2M. Regarding current trading prices, BIO.AX is priced at A$0.38, while SPL.AX trades at A$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas SPL.AX's P/E ratio is -41.00. In terms of profitability, BIO.AX's ROE is +0.18%, compared to SPL.AX's ROE of -0.16%. Regarding short-term risk, BIO.AX is less volatile compared to SPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check SPL.AX's competition here
BIO.AX vs RCE.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, RCE.AX has a market cap of 137.4M. Regarding current trading prices, BIO.AX is priced at A$0.38, while RCE.AX trades at A$0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas RCE.AX's P/E ratio is -4.32. In terms of profitability, BIO.AX's ROE is +0.18%, compared to RCE.AX's ROE of +2.79%. Regarding short-term risk, BIO.AX is more volatile compared to RCE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check RCE.AX's competition here
BIO.AX vs ACW.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ACW.AX has a market cap of 132.3M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ACW.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ACW.AX's P/E ratio is -3.70. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ACW.AX's ROE of -1.34%. Regarding short-term risk, BIO.AX is more volatile compared to ACW.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ACW.AX's competition here
BIO.AX vs PAR.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, PAR.AX has a market cap of 114.2M. Regarding current trading prices, BIO.AX is priced at A$0.38, while PAR.AX trades at A$0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas PAR.AX's P/E ratio is -2.60. In terms of profitability, BIO.AX's ROE is +0.18%, compared to PAR.AX's ROE of -2.66%. Regarding short-term risk, BIO.AX is more volatile compared to PAR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PAR.AX's competition here
BIO.AX vs ILA.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ILA.AX has a market cap of 112.5M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ILA.AX trades at A$0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ILA.AX's P/E ratio is -15.00. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ILA.AX's ROE of -1.01%. Regarding short-term risk, BIO.AX is less volatile compared to ILA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check ILA.AX's competition here
BIO.AX vs PAA.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, BIO.AX's ROE is +0.18%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, BIO.AX is less volatile compared to PAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check PAA.AX's competition here
BIO.AX vs BOT.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, BOT.AX has a market cap of 108.7M. Regarding current trading prices, BIO.AX is priced at A$0.38, while BOT.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas BOT.AX's P/E ratio is -0.98. In terms of profitability, BIO.AX's ROE is +0.18%, compared to BOT.AX's ROE of -1.31%. Regarding short-term risk, BIO.AX is less volatile compared to BOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check BOT.AX's competition here
BIO.AX vs NYR.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, NYR.AX has a market cap of 102.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while NYR.AX trades at A$0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas NYR.AX's P/E ratio is -25.75. In terms of profitability, BIO.AX's ROE is +0.18%, compared to NYR.AX's ROE of -0.83%. Regarding short-term risk, BIO.AX is less volatile compared to NYR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check NYR.AX's competition here
BIO.AX vs ALA.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ALA.AX has a market cap of 89.3M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ALA.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ALA.AX's P/E ratio is -7.40. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ALA.AX's ROE of -0.41%. Regarding short-term risk, BIO.AX is more volatile compared to ALA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ALA.AX's competition here
BIO.AX vs ATH.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ATH.AX has a market cap of 87M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ATH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ATH.AX's P/E ratio is -0.80. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ATH.AX's ROE of -0.30%. Regarding short-term risk, BIO.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check ATH.AX's competition here
BIO.AX vs CYP.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, CYP.AX has a market cap of 73.6M. Regarding current trading prices, BIO.AX is priced at A$0.38, while CYP.AX trades at A$0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas CYP.AX's P/E ratio is -7.75. In terms of profitability, BIO.AX's ROE is +0.18%, compared to CYP.AX's ROE of -1.79%. Regarding short-term risk, BIO.AX is more volatile compared to CYP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CYP.AX's competition here
BIO.AX vs NUZ.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, NUZ.AX has a market cap of 67.1M. Regarding current trading prices, BIO.AX is priced at A$0.38, while NUZ.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas NUZ.AX's P/E ratio is -3.20. In terms of profitability, BIO.AX's ROE is +0.18%, compared to NUZ.AX's ROE of -2.54%. Regarding short-term risk, BIO.AX is less volatile compared to NUZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check NUZ.AX's competition here
BIO.AX vs IMM.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, IMM.AX has a market cap of 66.2M. Regarding current trading prices, BIO.AX is priced at A$0.38, while IMM.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas IMM.AX's P/E ratio is -0.75. In terms of profitability, BIO.AX's ROE is +0.18%, compared to IMM.AX's ROE of -0.69%. Regarding short-term risk, BIO.AX is less volatile compared to IMM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check IMM.AX's competition here
BIO.AX vs PTX.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, PTX.AX has a market cap of 61M. Regarding current trading prices, BIO.AX is priced at A$0.38, while PTX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas PTX.AX's P/E ratio is -5.80. In terms of profitability, BIO.AX's ROE is +0.18%, compared to PTX.AX's ROE of -0.62%. Regarding short-term risk, BIO.AX is less volatile compared to PTX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check PTX.AX's competition here
BIO.AX vs IMU.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, IMU.AX has a market cap of 59.5M. Regarding current trading prices, BIO.AX is priced at A$0.38, while IMU.AX trades at A$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas IMU.AX's P/E ratio is -0.80. In terms of profitability, BIO.AX's ROE is +0.18%, compared to IMU.AX's ROE of -1.35%. Regarding short-term risk, BIO.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check IMU.AX's competition here
BIO.AX vs ATX.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ATX.AX has a market cap of 59M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ATX.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ATX.AX's P/E ratio is -5.75. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ATX.AX's ROE of -0.25%. Regarding short-term risk, BIO.AX is less volatile compared to ATX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check ATX.AX's competition here
BIO.AX vs ENP.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ENP.AX has a market cap of 55M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ENP.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ENP.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ENP.AX's ROE of -1.05%. Regarding short-term risk, BIO.AX is less volatile compared to ENP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check ENP.AX's competition here
BIO.AX vs PIQ.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, PIQ.AX has a market cap of 52.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while PIQ.AX trades at A$0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas PIQ.AX's P/E ratio is -4.57. In terms of profitability, BIO.AX's ROE is +0.18%, compared to PIQ.AX's ROE of -0.94%. Regarding short-term risk, BIO.AX is more volatile compared to PIQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PIQ.AX's competition here
BIO.AX vs RAD.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, RAD.AX has a market cap of 52M. Regarding current trading prices, BIO.AX is priced at A$0.38, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas RAD.AX's P/E ratio is -1.10. In terms of profitability, BIO.AX's ROE is +0.18%, compared to RAD.AX's ROE of -0.93%. Regarding short-term risk, BIO.AX is less volatile compared to RAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check RAD.AX's competition here
BIO.AX vs EZZ.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, EZZ.AX has a market cap of 48M. Regarding current trading prices, BIO.AX is priced at A$0.38, while EZZ.AX trades at A$1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas EZZ.AX's P/E ratio is 17.00. In terms of profitability, BIO.AX's ROE is +0.18%, compared to EZZ.AX's ROE of +0.10%. Regarding short-term risk, BIO.AX is less volatile compared to EZZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check EZZ.AX's competition here
BIO.AX vs ADO.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ADO.AX has a market cap of 35.7M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ADO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ADO.AX's P/E ratio is -1.20. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ADO.AX's ROE of -1.42%. Regarding short-term risk, BIO.AX is less volatile compared to ADO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check ADO.AX's competition here
BIO.AX vs NSB.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, NSB.AX has a market cap of 30.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while NSB.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas NSB.AX's P/E ratio is -4.65. In terms of profitability, BIO.AX's ROE is +0.18%, compared to NSB.AX's ROE of -0.19%. Regarding short-term risk, BIO.AX is more volatile compared to NSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check NSB.AX's competition here
BIO.AX vs AVE.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, AVE.AX has a market cap of 29.7M. Regarding current trading prices, BIO.AX is priced at A$0.38, while AVE.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas AVE.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.18%, compared to AVE.AX's ROE of -3.70%. Regarding short-term risk, BIO.AX is more volatile compared to AVE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check AVE.AX's competition here
BIO.AX vs AGN.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, AGN.AX has a market cap of 28.3M. Regarding current trading prices, BIO.AX is priced at A$0.38, while AGN.AX trades at A$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas AGN.AX's P/E ratio is -2.75. In terms of profitability, BIO.AX's ROE is +0.18%, compared to AGN.AX's ROE of -1.84%. Regarding short-term risk, BIO.AX is less volatile compared to AGN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check AGN.AX's competition here
BIO.AX vs 1AI.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, 1AI.AX has a market cap of 25.7M. Regarding current trading prices, BIO.AX is priced at A$0.38, while 1AI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas 1AI.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.18%, compared to 1AI.AX's ROE of -0.49%. Regarding short-term risk, BIO.AX is less volatile compared to 1AI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check 1AI.AX's competition here
BIO.AX vs LCT.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, BIO.AX is priced at A$0.38, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.18%, compared to LCT.AX's ROE of -0.62%. Regarding short-term risk, BIO.AX is more volatile compared to LCT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check LCT.AX's competition here
BIO.AX vs NC6.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, NC6.AX has a market cap of 23.2M. Regarding current trading prices, BIO.AX is priced at A$0.38, while NC6.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas NC6.AX's P/E ratio is -7.10. In terms of profitability, BIO.AX's ROE is +0.18%, compared to NC6.AX's ROE of -19.65%. Regarding short-term risk, BIO.AX is more volatile compared to NC6.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check NC6.AX's competition here
BIO.AX vs KZA.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, BIO.AX's ROE is +0.18%, compared to KZA.AX's ROE of -26.34%. Regarding short-term risk, BIO.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check KZA.AX's competition here
BIO.AX vs NOX.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, NOX.AX has a market cap of 18.7M. Regarding current trading prices, BIO.AX is priced at A$0.38, while NOX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas NOX.AX's P/E ratio is -3.05. In terms of profitability, BIO.AX's ROE is +0.18%, compared to NOX.AX's ROE of +25.10%. Regarding short-term risk, BIO.AX is more volatile compared to NOX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check NOX.AX's competition here
BIO.AX vs BTC.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, BTC.AX has a market cap of 18.3M. Regarding current trading prices, BIO.AX is priced at A$0.38, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas BTC.AX's P/E ratio is 5.90. In terms of profitability, BIO.AX's ROE is +0.18%, compared to BTC.AX's ROE of -0.10%. Regarding short-term risk, BIO.AX is more volatile compared to BTC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check BTC.AX's competition here
BIO.AX vs MEM.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, MEM.AX has a market cap of 15.7M. Regarding current trading prices, BIO.AX is priced at A$0.38, while MEM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas MEM.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.18%, compared to MEM.AX's ROE of -0.92%. Regarding short-term risk, BIO.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check MEM.AX's competition here
BIO.AX vs MDC.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, BIO.AX is priced at A$0.38, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas MDC.AX's P/E ratio is -0.01. In terms of profitability, BIO.AX's ROE is +0.18%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, BIO.AX is more volatile compared to MDC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check MDC.AX's competition here
BIO.AX vs BNO.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, BIO.AX is priced at A$0.38, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, BIO.AX's ROE is +0.18%, compared to BNO.AX's ROE of +0.45%. Regarding short-term risk, BIO.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check BNO.AX's competition here
BIO.AX vs CMB.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, CMB.AX has a market cap of 11M. Regarding current trading prices, BIO.AX is priced at A$0.38, while CMB.AX trades at A$0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas CMB.AX's P/E ratio is -3.43. In terms of profitability, BIO.AX's ROE is +0.18%, compared to CMB.AX's ROE of -2.19%. Regarding short-term risk, BIO.AX is more volatile compared to CMB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CMB.AX's competition here
BIO.AX vs PAB.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, PAB.AX has a market cap of 10.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while PAB.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas PAB.AX's P/E ratio is -1.60. In terms of profitability, BIO.AX's ROE is +0.18%, compared to PAB.AX's ROE of -4.06%. Regarding short-term risk, BIO.AX is less volatile compared to PAB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check PAB.AX's competition here
BIO.AX vs BGT.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, BGT.AX has a market cap of 10.7M. Regarding current trading prices, BIO.AX is priced at A$0.38, while BGT.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas BGT.AX's P/E ratio is -3.50. In terms of profitability, BIO.AX's ROE is +0.18%, compared to BGT.AX's ROE of -1.40%. Regarding short-term risk, BIO.AX is less volatile compared to BGT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check BGT.AX's competition here
BIO.AX vs TRP.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, TRP.AX has a market cap of 10.3M. Regarding current trading prices, BIO.AX is priced at A$0.38, while TRP.AX trades at A$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas TRP.AX's P/E ratio is -2.83. In terms of profitability, BIO.AX's ROE is +0.18%, compared to TRP.AX's ROE of -0.30%. Regarding short-term risk, BIO.AX is less volatile compared to TRP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check TRP.AX's competition here
BIO.AX vs CHM.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, CHM.AX has a market cap of 8.8M. Regarding current trading prices, BIO.AX is priced at A$0.38, while CHM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas CHM.AX's P/E ratio is -0.20. In terms of profitability, BIO.AX's ROE is +0.18%, compared to CHM.AX's ROE of +28.45%. Regarding short-term risk, BIO.AX is more volatile compared to CHM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CHM.AX's competition here
BIO.AX vs IMC.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, IMC.AX has a market cap of 8M. Regarding current trading prices, BIO.AX is priced at A$0.38, while IMC.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas IMC.AX's P/E ratio is -1.55. In terms of profitability, BIO.AX's ROE is +0.18%, compared to IMC.AX's ROE of -0.44%. Regarding short-term risk, BIO.AX is more volatile compared to IMC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check IMC.AX's competition here
BIO.AX vs IXC.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, IXC.AX has a market cap of 7.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while IXC.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas IXC.AX's P/E ratio is -10.50. In terms of profitability, BIO.AX's ROE is +0.18%, compared to IXC.AX's ROE of -0.17%. Regarding short-term risk, BIO.AX is more volatile compared to IXC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check IXC.AX's competition here
BIO.AX vs VBS.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, VBS.AX has a market cap of 6.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while VBS.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas VBS.AX's P/E ratio is -4.33. In terms of profitability, BIO.AX's ROE is +0.18%, compared to VBS.AX's ROE of +2.65%. Regarding short-term risk, BIO.AX is more volatile compared to VBS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check VBS.AX's competition here
BIO.AX vs ZLD.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ZLD.AX has a market cap of 5.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ZLD.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ZLD.AX's P/E ratio is -1.56. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ZLD.AX's ROE of +0.56%. Regarding short-term risk, BIO.AX is more volatile compared to ZLD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ZLD.AX's competition here
BIO.AX vs BIT.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, BIT.AX has a market cap of 4.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas BIT.AX's P/E ratio is -0.30. In terms of profitability, BIO.AX's ROE is +0.18%, compared to BIT.AX's ROE of -1.19%. Regarding short-term risk, BIO.AX is more volatile compared to BIT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check BIT.AX's competition here
BIO.AX vs ACR.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ACR.AX has a market cap of 4.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ACR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ACR.AX's P/E ratio is -1.20. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ACR.AX's ROE of -2.12%. Regarding short-term risk, BIO.AX is more volatile compared to ACR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ACR.AX's competition here
BIO.AX vs RGS.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, BIO.AX is priced at A$0.38, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, BIO.AX's ROE is +0.18%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, BIO.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check RGS.AX's competition here
BIO.AX vs HXL.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, HXL.AX has a market cap of 2.2M. Regarding current trading prices, BIO.AX is priced at A$0.38, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas HXL.AX's P/E ratio is -1.30. In terms of profitability, BIO.AX's ROE is +0.18%, compared to HXL.AX's ROE of -0.32%. Regarding short-term risk, BIO.AX is more volatile compared to HXL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check HXL.AX's competition here
BIO.AX vs ANR.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, ANR.AX has a market cap of 2.1M. Regarding current trading prices, BIO.AX is priced at A$0.38, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas ANR.AX's P/E ratio is -1.00. In terms of profitability, BIO.AX's ROE is +0.18%, compared to ANR.AX's ROE of -1.09%. Regarding short-term risk, BIO.AX is more volatile compared to ANR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ANR.AX's competition here
BIO.AX vs EX1.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, BIO.AX is priced at A$0.38, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, BIO.AX's ROE is +0.18%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, BIO.AX is more volatile compared to EX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check EX1.AX's competition here
BIO.AX vs 1AD.AX Comparison March 2026
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 85.7M. In comparison, 1AD.AX has a market cap of 522.2K. Regarding current trading prices, BIO.AX is priced at A$0.38, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -38.50, whereas 1AD.AX's P/E ratio is -0.40. In terms of profitability, BIO.AX's ROE is +0.18%, compared to 1AD.AX's ROE of +10.68%. Regarding short-term risk, BIO.AX is more volatile compared to 1AD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check 1AD.AX's competition here